Us Bancorp \De\ Cellectis S.A. Transaction History

Us Bancorp \De\

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$2.39 - $4.93 $4,741 - $9,781	-1,984 Reduced 99.5%	10 $0
Q1 2022 May 11, 2022	SELL	$3.45 - $8.77 $13,524 - $34,378	-3,920 Reduced 66.28%	1,994 $9,000
Q4 2021 Feb 11, 2022	BUY	$8.01 - $12.84 $28,691 - $45,992	3,582 Added 153.6%	5,914 $48,000
Q3 2021 Nov 10, 2021	BUY	$11.94 - $16.09 $13,492 - $18,181	1,130 Added 94.01%	2,332 $29,000
Q2 2021 Aug 05, 2021	SELL	$14.36 - $20.93 $9,362 - $13,646	-652 Reduced 35.17%	1,202 $19,000
Q1 2021 Apr 28, 2021	SELL	$18.19 - $33.25 $2,000 - $3,657	-110 Reduced 5.6%	1,854 $37,000
Q4 2020 Feb 04, 2021	BUY	$15.87 - $31.64 $6,379 - $12,719	402 Added 25.74%	1,964 $53,000
Q3 2020 Nov 10, 2020	SELL	$15.7 - $20.84 $486 - $646	-31 Reduced 1.95%	1,562 $29,000
Q2 2020 Aug 07, 2020	BUY	$8.21 - $21.02 $2,036 - $5,212	248 Added 18.44%	1,593 $29,000
Q1 2020 May 13, 2020	SELL	$7.81 - $18.82 $312 - $752	-40 Reduced 2.89%	1,345 $12,000
Q4 2019 Feb 04, 2020	SELL	$9.73 - $19.31 $4,271 - $8,477	-439 Reduced 24.07%	1,385 $24,000
Q3 2019 Nov 08, 2019	BUY	$10.15 - $16.89 $17,234 - $28,679	1,698 Added 1347.62%	1,824 $19,000
Q2 2019 Aug 13, 2019	SELL	$14.6 - $20.6 $2,336 - $3,296	-160 Reduced 55.94%	126 $2,000
Q1 2019 May 08, 2019	BUY	$15.53 - $19.75 $4,441 - $5,648	286 New	286 $5,000
Q3 2018 Nov 01, 2018	SELL	$25.99 - $30.6 $10,785 - $12,699	-415 Closed	0 $0
Q2 2018 Aug 08, 2018	BUY	$27.78 - $38.53 $11,528 - $15,989	415 New	415 $12,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.